K. Boman

发表

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.

G. Horvath, B. Sorbe, M. Graflund, 2011, International journal of oncology.

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

P. Zola, A. Lissoni, S. Grénman, 2010, European journal of cancer.

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

I. Vergote, G. Kristensen, K. Lindemann, 2014, BMC Cancer.

Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase.

T. Bäckström, S. Cajander, K. Boman, 1999, The Journal of clinical endocrinology and metabolism.

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

T. Ciuleanu, M. Wojtukiewicz, C. Lebedinsky, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Endometrial carcinoma : steroid hormones and receptors in relation to proliferation

K. Boman, 1993 .

Human 17β‐Hydroxysteroid Dehydrogenase in Normal and Malignant Endometrium a

R. Vihko, V. Lehto, O. Mäentausta, 1991 .

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long- term follow- up

H. Andersson, P. Rosenberg, B. Sorbe, 2007, International Journal of Gynecologic Cancer.

Immunohistochemical study of the human 17β‐hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma

R. Vihko, O. Mäentausta, V. Isomaa, 1992, Cancer.

Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis.

T. Bäckström, S. Cajander, K. Boman, 2003, International journal of oncology.

A Systematic Overview of Radiation Therapy Effects in Cervical Cancer (Cervix Uteri)

C. Tropé, E. Cavallin-ståhl, N. Einhorn†, 2003, Acta oncologica.

A Systematic Overview of Radiation Therapy Effects in Ovarian Cancer

C. Tropé, E. Cavallin-ståhl, N. Einhorn†, 2003, Acta oncologica.

External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.

H. Andersson, G. Horvath, B. Sorbe, 2012, International journal of radiation oncology, biology, physics.

External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma: A Prospective, Randomized Study—Quality-of-Life Analysis

H. Andersson, G. Horvath, B. Sorbe, 2012, International Journal of Gynecologic Cancer.

Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.

T. Bäckström, S. Cajander, K. Boman, 2004, Gynecologic oncology.

A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum‐induced nausea and emesis

T. Högberg, H. Andersson, B. Sorbe, 1998, Cancer.

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

I. Vergote, J. Huober, I. Ray-Coquard, 2011, Gynecologic oncology.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

R. Vihko, V. Lehto, O. Mäentausta, 2006 .

Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.

Yan Shen, Kui Liu, P. Reddy, 2005, Molecular endocrinology.

Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a

Yan Shen, Kui Liu, C. Du, 2007, Development.

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.

B. Monk, D. Provencher, Y. Park, 2011, Gynecologic oncology.

Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development.

Kui Liu, Yi-Xun Liu, P. Reddy, 2005, Developmental biology.

Control of mammalian oocyte growth and early follicular development by the oocyte PI3 kinase pathway: new roles for an old timer.

Kui Liu, P. Reddy, G. Selstam, 2006, Developmental biology.

Phosphorylation and inactivation of glycogen synthase kinase-3 by soluble kit ligand in mouse oocytes during early follicular development.

Yan Shen, Kui Liu, C. Du, 2007, Journal of molecular endocrinology.

The influence of progesterone and androgens on the growth of endometrial carcinoma

P. Strang, T. Bäckström, U. Stendahl, 1993, Cancer.

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

G. Horvath, B. Sorbe, M. Graflund, 2012, International Journal of Gynecologic Cancer.

A Systematic Overview of Radiation Therapy Effects in Uterine Cancer (Corpus Uteri)

C. Tropé, E. Cavallin-ståhl, N. Einhorn†, 2003, Acta oncologica.

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

U. Puistola, P. Rosenberg, B. Sorbe, 2002, Acta oncologica.

Influence of oestrogen on growth of endometrial carcinoma.

P. Strang, T. Bäckström, U. Stendahl, 1990, Anticancer research.

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

A. Jacobsen, U. Puistola, C. Tropé, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC

S. Loibl, J. Huober, C. Jackisch, 2005 .

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel

H. Andersson, P. Rosenberg, B. Sorbe, 2005 .

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

J. Sehouli, N. Colombo, A. Nieto, 2011 .

Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma

D. Lindquist, E. Lundin, A. Patthey, 2021, Acta oncologica.

Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.

T. Ciuleanu, A. Poveda, M. Izquierdo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Informed consent and participants’ inclination to delegate decision-making to the doctor

N. Lynöe, H. Andersson, M. Sandlund, 2004, Acta oncologica.

Phosphorylation and inactivation of glycogen synthase kinase-3 by soluble kit ligand in mouse oocytes during early follicular development.

Yan Shen, Kui Liu, C. Du, 2007, Journal of molecular endocrinology.

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

P. Zola, A. Lissoni, S. Grénman, 2010, European journal of cancer.

Immunohistochemical study of the human 17β‐hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma

R. Vihko, O. Mäentausta, V. Isomaa, 1992, Cancer.